SCHEMBL4243105

SCHEMBL4243105

COC(=O)CCc1ccccc1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.57
LMNA P02545 2/20 0.57
FOLH1 Q04609 1/20 0.56
TDP1 Q9NUW8 1/20 0.48
TSHR P16473 3/20 0.47
CYP2C9 P11712 1/20 0.47
HIF1A Q16665 1/20 0.47
SLC16A3 O15427 2/20 0.46
CYP4F2 P78329 1/20 0.45
CYP4A11 Q02928 1/20 0.45
KDM4E B2RXH2 3/20 0.45
HPGD P15428 1/20 0.45
HSD17B10 Q99714 1/20 0.45
CA12 O43570 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
CLCN2 P51788 1/20 0.44
ALOX15 P16050 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27552 0.86 ALDH1A1 (0.76) ALDH1A1LMNATDP1TSHRHIF1A
SCHEMBL9844983 0.85 ALDH1A1 (0.53) ALDH1A1LMNATDP1TSHRCYP2C9
SCHEMBL10438855 0.85 CYP4F2 (0.58) ALDH1A1LMNATDP1TSHRCYP4F2
SCHEMBL8695949 0.85 HTT (0.56) ALDH1A1LMNATDP1TSHRKDM4E
Phthalic Acid SCHEMBL28233805 0.83 ALDH1A1 (0.58) ALDH1A1LMNATSHRKDM4EHPGD
SCHEMBL23884678 0.83 CYP4F2 (0.67) ALDH1A1LMNAFOLH1TDP1TSHR
SCHEMBL7380269 0.83 ALDH1A1 (0.64) ALDH1A1LMNAKDM4EHPGDHSD17B10
SCHEMBL3916488 0.82 FOLH1 (0.50) ALDH1A1LMNAFOLH1TSHRCYP2C9
SCHEMBL6802490 0.82 FOLH1 (0.51) ALDH1A1LMNAFOLH1TSHRCYP2C9
SCHEMBL30339213 0.82 FOLH1 (0.51) ALDH1A1LMNAFOLH1TSHRCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12234202-B2 Covalent inhibitors of coronavirus papain-like protease UT-BATTELLE, LLC (US) 2025-02-25 US disclosed
US-20240317707-A1 COVALENT AND NON-COVALENT INHIBITORS OF CORONAVIRUS PAPAIN-LIKE PROTEASE U. S. DEPARTMENT OF ENERGY 2024-09-26 US disclosed
US-20240245673-A1 Papain-like protease (PLpro) inhibitors PFIZER INC. (US) 2024-07-25 US disclosed
WO-2024121779-A1 PAPAIN-LIKE PROTEASE (PLPRO) INHIBITORS PFIZER INC. (US) 2024-06-13 WO disclosed
WO-2024121709-A1 PAPAIN-LIKE PROTEASE (PLPRO) INHIBITORS PFIZER INC. (US) 2024-06-13 WO disclosed
WO-2023223055-A1 ANTI-VIRAL COMPOUNDS Infex Therapeutics Limited (GB) 2023-11-23 WO disclosed
WO-2023064493-A1 COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES Clear Creek Bio, Inc. (US) 2023-04-20 WO disclosed
US-20230102656-A1 COVALENT INHIBITORS OF CORONAVIRUS PAPAIN-LIKE PROTEASE U. S. DEPARTMENT OF ENERGY 2023-03-30 US disclosed
WO-2023028286-A1 COVALENT INHIBITORS OF CORONAVIRUS PAPAIN-LIKE PROTEASE UT-BATTELLE, LLC (US) 2023-03-02 WO disclosed
US-9328057-B2 Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases DOMPE' FARMACEUTICI S.P.A. (IT) 2016-05-03 US disclosed
WO-2002051810-A2 INTEGRIN RECEPTOR LIGANDS ABBOTT GMBH & CO. KG (DE) 2002-07-04 WO disclosed
US-20020019416-A1 ESTERS AND AMIDES AS PLA2 INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-02-14 US disclosed
CN-1056602-C Esters and amides as PLA2 inhibitors FUJISAWA PHARMACEUTICAL CO (JP) 2000-09-20 CN disclosed
CN-1197450-A Esters and amides as phospholipase A2 inhibitors FUJISAWA PHARMACEUTICAL CO (JP) 1998-10-28 CN disclosed
EP-0854863-A1 ESTERS AND AMIDES AS PLA2 INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-07-29 EP disclosed
WO-1997003951-A1 ESTERS AND AMIDES AS PLA2 INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-02-06 WO disclosed
US-4885313-A 3,4-Dihydroxyphenylethylamine derivatives and their use FISONS PLC (GB) 1989-12-05 US disclosed
US-4803225-A Dihydroxy-phenethylamino compounds useful as pharmaceuticals FISONS, PLC (GB) 1989-02-07 US disclosed
US-4720586-A Substituted 3,4-dihydroxy-phenylethylamino compounds FISONS, PLC (GB) 1988-01-19 US disclosed
EP-0142283-A2 Phenylethylamines, process for their preparation and compositions containing them FISONS plc (GB) 1985-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12234202-B2 Covalent inhibitors of coronavirus papain-like protease CPN1, CTRL, CTRC ALDH1A1 1621/4885LMNA 2147/4885FOLH1 1205/4885
US-20230102656-A1 COVALENT INHIBITORS OF CORONAVIRUS PAPAIN-LIKE PROTEASE CPN1, CTRL, CTRC ALDH1A1 1621/4885LMNA 2147/4885FOLH1 1205/4885
US-20240245673-A1 Papain-like protease (PLpro) inhibitors PREP, PEPD, ACE ALDH1A1 2220/4885LMNA 1294/4885FOLH1 634/4885
US-20020019416-A1 ESTERS AND AMIDES AS PLA2 INHIBITORS PLA2G4A, PLA2G4B, PLA2G1B ALDH1A1 700/4885LMNA 3290/4885FOLH1 3878/4885
US-20240317707-A1 COVALENT AND NON-COVALENT INHIBITORS OF CORONAVIRUS PAPAIN-LIKE PROTEASE HPN, CTRL, CPN1 ALDH1A1 2872/4885LMNA 4032/4885FOLH1 911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.